First AbbVie chopped a PhIII, then they wrote off $4B in book value. Now 178 Stemcentrx workers are getting the ax
AbbVie is steadily chopping away at the people and programs they brought into the company with their big $10 billion Stemcentrx buyout deal. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
